WHO Raises Concern Over Critical Shortage of Obesity Medications
Under one in 10 individuals eligible to benefit from obesity jabs like Wegovy are able to get them, caution the WHO as it publishes its inaugural guidance on the medications.
With over a billion individuals worldwide currently living with obesity, it is calling for more widespread and fairer availability to GLP-1 medication.
According to projections, in excess of 2,000,000,000 will be living with obesity by 2030 without intervention.
"The new guidance acknowledges that obesity is a lifelong illness that can be managed with holistic and lifelong care," said the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and logistical bottlenecks are major barriers to universal availability to the jabs that can help people shift considerable weight, notes the agency.
Skinny Jab Scarcity
Even in the current most optimistic case, the manufacturing of GLP-1 therapies would only suffice for approximately 100 million people – less than 10% of those who need them, as stated by the health organization.
The guideline calls on nations and manufacturers to expand availability, through measures such as licensing agreements.
A patent on a key compound – the main component of a leading brand – is scheduled to end in multiple nations in 2026.
How Obesity Jabs Work
The injections mimick a natural hormone to delay gastric emptying, suppress the appetite and boost the sense of being full so people reduce food intake.
Individuals commonly see weight reduction in the initial weeks of commencing the regular doses.
Studies points to patients may regain a significant portion a year later of halting the drug, when their normal food cravings return.
To be overweight or obese elevates your likelihood for developing diseases, such as type 2 diabetes, cardiovascular issues, brain attack, and certain malignancies.
Obesity affects people in every country and was associated with 3.7 million fatalities worldwide in 2024, according to the WHO.
